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Abstract: TPK1 mutations are a rare, but potentially treatable, cause of thiamine deficiency.
Diagnosis is challenging given the phenotypic overlap that exists with other metabolic and neurological
disorders. We report a case of TPK1-related disease presenting with Leigh-like syndrome and
review the diagnostic utility of thiamine pyrophosphate (TPP) blood measurement. The proband,
a 35-year-old male, presented at four months of age with recurrent episodes of post-infectious
encephalopathy. He subsequently developed epilepsy, learning difficulties, sensorineural hearing
loss, spasticity, and dysphagia. There was a positive family history for Leigh syndrome in an older
brother. Plasma lactate was elevated (3.51 mmol/L) and brain MRI showed bilateral basal ganglia
hyperintensities, indicative of Leigh syndrome. Histochemical and spectrophotometric analysis of
mitochondrial respiratory chain complexes I, II+III, and IV was normal. Genetic analysis of muscle
mitochondrial DNA was negative. Whole exome sequencing of the proband confirmed compound
heterozygous variants in TPK1: c. 426G>C (p. Leu142Phe) and c. 258+1G>A (p.?). Blood TPP levels
were reduced, providing functional evidence for the deleterious effects of the variants. We highlight
the clinical and bioinformatics challenges to diagnosing rare genetic disorders and the continued utility
of biochemical analyses, despite major advances in DNA sequencing technology, when investigating
novel, potentially disease-causing, genetic variants. Blood TPP measurement represents a fast and
cost-effective diagnostic tool in TPK1-related diseases.
Keywords: mitochondrial diseases; TPK1; thiamine pyrophosphate; Leigh syndrome;
thiamine deficiency
1. Introduction
Genetic disorders of thiamine transport and metabolism are a rare but treatable cause of
thiamine deficiency that usually present during childhood [1]. Four genetic defects are reported;
three present with a predominantly neurological phenotype (SLC19A3, SLC25A19 and TPK1) and one
with multisystem disease (SLC19A2), including megaloblastic anaemia, thrombocytopenia, diabetes,
and hearing loss. Thiamine pyrophosphokinase 1 (hTPK1, EC2.7.6.2), encoded by TPK1, converts free
thiamine to active thiamine pyrophosphate (TPP). Early recognition is therefore crucial given the
potential benefits of thiamine supplementation. However, diagnosis of TPK1-related diseases is often
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delayed because of the clinical overlap with other metabolic diseases, including Leigh syndrome.
Consequently, patients often undergo numerous investigations, including muscle and skin biopsies,
prior to receiving a molecular diagnosis. Here, we describe a case of TPK1-related disease that
highlights the potential applications of whole blood TPP measurement for diagnosis and subsequent
biochemical monitoring following thiamine supplementation.
2. Case Presentation
The proband, the fourth child of healthy unrelated parents, was an uncomplicated pregnancy and
delivery and reached all early motor milestones without delays. An older brother had been diagnosed
with Leigh syndrome in the early childhood, while two older siblings were healthy. He presented
with a post-viral encephalopathy aged four months following varicella-zoster infection and at nine
months sensorineural hearing loss was detected. He subsequently experienced recurrent episodes of
encephalopathy associated with intercurrent infection and was diagnosed with learning difficulties
and seizures. At 22 years he was evaluated in a specialist mitochondrial clinic. At this time, he required
fulltime use of a wheelchair and, despite improved seizure control with dual anticonvulsant therapy,
continued to experience daily episodes of focal impaired awareness. Neurological examination
revealed optic disc atrophy and sensorineural hearing loss. In limbs, there was a spastic increase
in tone, hyper-reflexia, and bilateral extensor plantar responses. Laboratory tests, including CPK,
fasting acylcarnitine profile, and very long chain fatty acids, were normal. Plasma lactate was
elevated (3.51 mmol/L, reference range 0.5–2.22 mmol/L). Brain MRI revealed bilateral, symmetrical T2
hyperintensities in the corpus striatum and severe cerebellar and moderate brainstem volume loss,
without signal abnormalities (Figure 1). The cervical spinal cord displayed normal imaging appearances.
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Pyruvate dehydrogenase complex (PDC) activity in cultured fibroblasts, and histological, 
histochemical, and mitochondrial respiratory chain enzyme analyses of skeletal muscle tissue, was 
normal. Sanger sequencing of the entire mitochondrial genome and molecular analysis for large scale 
mitochondrial DNA rearrangements using long range PCR were negative. Whole exome sequencing 
was performed using the proband’s genomic DNA extracted from peripheral leukocytes (Appendix 
A). Variants with a minor allele frequency (MAF) of ≥0.01 reported in gnomAD [2] and 1000 Genomes 
databases, and synonymous and deep intronic variants, were excluded. Recessive and X-linked 
inheritance patterns were prioritised (Supplementary Figure S1). First, a list of genes encoding 
mitochondrial-localized proteins (n = 1158, Mitocarta) [3] was analysed. A variant in NDUFA1 
(c.94G>C; p.Gly32Arg), previously reported in two cousins with a progressive neurodegenerative 
disorder associated with complex I deficiency [4], was identified. However, given the relatively high 
Figure 1. Brain MRI. (A) Axial image demonstrates bilateral, symmetrical T2-weighted high signal
intensities within the corpus striatum (arrows). (B) Sagittal image shows erebellar atrophy (asterisk).
Pyruvate dehydrogenase complex (PDC) activity in cultured fibroblasts, and histological,
histochemical, and mitochondrial respiratory chain enzyme analyses of skeletal muscle tissue,
was normal. Sanger sequencing of the entire mitochondrial genome and molecular analysis for
large scale mitochondrial DNA rearrangements using long range PCR were negative. Whole exome
sequencing was performed using the proband’s genomic DNA extracted from peripheral leukocytes
(Appendix A). Variants with a minor allele frequency (MAF) of ≥0.01 reported in gnomAD [2] and
1000 Genomes databases, and synonymous and deep intronic variants, were excluded. Recessive and
X-linked inheritance patterns were prioritised (Supplementary Figure S1). First, a list of genes encoding
mitochondrial-localized proteins (n= 1158, Mitocarta) [3] was analysed. A variant inNDUFA1 (c.94G>C;
p.Gly32Arg), previously reported in two cousins with a progressive neurodegenerative disorder
associated with complex I deficiency [4], was identified. However, given the relatively high MAF
reported in gnomAD (1189/205094, 408 hemizygotes, MAF 0.005797), and the normality of mitochondrial
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respiratory chain complex I enzyme activity in the proband’s muscle tissue, additional screening
of variants detected in all remaining coding genes was undertaken. This revealed two missense
mutations in TPK1: c.426G>C; p.Leu142Phe (MAF 0.000028 in gnomAD), which exists within a highly
conserved region within the catalytic domain of hTPK1 (Figure 2A); and c.258+1G>A, residing in
the donor splice site of intron 5 (Supplementary Figure S2). Segregation studies in affected and
unaffected family members confirmed that both variants were in trans in the proband and his affected
brother. Importantly, the NDUFA1 variant failed to segregate with the disease (Figure 2B). TPP levels
in the proband were low (35 nmol/L, reference range 67–265), providing biochemical support for the
pathogenic effects of the variants, while hTPK1 steady state protein levels were reduced (Figure 2C),
consistent with previous reports of TPK1 mutations (see Appendix A for detailed methods) [5].
No additional bands were detected during the western blot analysis, indicating that the splicing
variant most likely causes an unstable mRNA molecule. Oral thiamine, 100 mg twice a day, was
commenced. Following the most recent assessment, TPP levels had increased to 59 nmol/L and lactate
had normalized (1.74 mmol/L). However, no meaningful clinical improvement was observed.
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of both TPK1 variants. (A) Conservation of hTPK1 amino acid sequence between species. The L142 
residue is highly conserved and resides within the catalytic domain of the protein. (B) Family pedigree 
and segregation analysis. NDUFA1 variant: c.94G>C. TPK1 variants (bold): c.426G>C and c.258+1G>A. 
(C) Steady state hTPK1 protein levels in patient fibroblasts. Abbreviations: GPI, glucose-6-phosphate 
isomerase (loading control); C, healthy control; D1 and D2, positive controls—previously reported as 
P2 and P5, respectively (Mayr et al., 2011) [6]; PT, proband in present study. 
Figure 2. Domain and amino acid conservation for the c.426G>C; p.Leu142Phe variant, and segregation
studies and impact on thiamine pyrophosphokinase 1 (TPK1) protein steady state levels of both TPK1
variants. (A) Conservation of hTPK1 amino acid sequence between species. The L142 residue is highly
conserved and resides within the catalytic domain of the protein. (B) Family pedigree and segregation
analysis. NDUFA1 variant: c.94G>C. TPK1 variants (bold): c.426G>C and c.258+1G>A. (C) Steady
state hTPK1 protein levels in patient fibroblasts. Abbreviations: GPI, glucose-6-phosphate isomerase
(loading control); C, healthy control; D1 and D2, positive controls—previously reported as P2 and P5,
respectively (Mayr et al., 2011) [6]; PT, proband in present study.
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3. Discussion
We report a new case of TPK1-related disease and highlight the clinical and diagnostic challenges
of these potentially treatable disorders.
Inherited diseases of thiamine metabolism impair the transport and activation of
thiamine. Thiamine exists in various phosphorylated states: unphosphorylated thiamine;
thiamine monophosphate (TMP); thiamine diphosphate/pyrophosphate (TPP); and thiamine
triphosphate (TTP) (Figure 3A). TPP is the active form of thiamine and acts as an important
co-factor for several enzymes that play a major role in energy metabolism, including pyruvate
dehydrogenase complex. Four primary genetic defects of thiamine metabolism are reported which
impair different stages of thiamine transport or activation (Figure 3B). These include: (1) thiamine
responsive megaloblastic anaemia (SLC19A2); (2) thiamine metabolism dysfunction syndrome 2
(biotin- or thiamine-responsive encephalopathy type 2, SLC19A3); (3) thiamine metabolism dysfunction
syndrome 5 (episodic encephalopathy type, TPK1); and (4) thiamine metabolism dysfunction syndrome
4 (progressive polyneuropathy type, SLC25A19).
SLC19A3-, TPK1-, and SLC25A19-related disorders present primarily with nervous system
phenotypes that are difficult to distinguish from isolated mitochondrial encephalopathy.
However, early recognition is important so that treatment with thiamine can be initiated. To facilitate
this process, diagnostic criteria have recently been established [5]. Unfortunately, given their rarity,
only limited data concerning TPK1-related diseases exists; only 13 patients are reported [5–10].
The majority of cases exhibited early onset, recurrent encephalopathic episodes, frequently triggered
by infection, followed by ataxia, epilepsy, pyramidal signs, and dystonia. One family presented with
progressive dystonia without recurrent encephalopathic episodes [10]. The clinical course of the disease
tends to be severe, with high levels of physical disability and reduced lifespan; of the 13 patients,
three died at 29 months, three, and eight years. There is no clear genotype–phenotype correlation and
the response to thiamine supplementation is variable [5].
Our case highlights the diagnostic challenges in TPK1-related diseases. The clinical phenotype
was compatible with Leigh syndrome, prompting investigations to exclude a mitochondrial disorder.
However, muscle histochemistry and respiratory chain enzyme activity were normal and consistent
with previous reports of TPK1-related disease. An unbiased next generation sequencing (NGS)
approach helped identify two missense TPK1 variants: c.426G>C (p.Leu142Phe) and c.258+1G>A
(p.?). The c.426G>C variant has been reported once in ClinVar and considered as a likely pathogenic
(RCV000255057). Interestingly, the c.425T>C variant affecting the same amino acid (p.Leu142Ser) has
also been reported in ClinVar (RCV000650011). However, no further clinical information is reported.
Given the molecular heterogeneity associated with Leigh syndrome, additional disease-causing
candidate genes were also considered. The NDUFA1 variant c.94G>C had been reported in two patients;
one with a progressive neurodegenerative disease associated with complex I deficiency, and one with
muscular hypotonia and lactic acidosis [4,11]. This association was supported by functional data in
hamster cell lines confirming reduced complex I activity [4]. Nevertheless, segregation studies and
analysis of recent MAF data among the general population suggests a non-pathogenic basis for the
variant [12]. The TPK1 variants were therefore considered the most likely cause of disease in our family.
The pathogenic effects were supported by segregation studies and a confirmed reduction in both
plasma TPP concentration and hTPK1 steady state protein levels. Thus, despite significant advances in
genomics, ancillary biochemical, and protein studies remain an important tool when investigating rare
genetic diseases.
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enzymatic pathways. Thiamine is phosphorylated to thiamine pyrophosphate (TPP) by thiamine
pyrophosphokinase 1 (hTPK1). It can be further phosphorylated to thiamine triphosphate (TTP) by
mitochondrial thiamine triphosphosphate synthase (ThTP synthase). It can also be dephosphorylated
by thiamine phosphatase (Th phosphatase) to thiamine monophosphate (TMP) and thiamine.
(B) Thiamine is absorbed in the small intestine and enters the cells using two transporters (e coded
by SLC19A2/SLC19A3) where it is pyrophosphorylated to the active form (TPP) by hTPK1. TPP is
transported into mitochondria by the SLC25A19 encoded carrier where it acts as a cofactor for three
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Despite the molecular heterogeneity exhibited by Leigh syndrome, TPP measurement represents
a cost and time effective strategy when investigating suspected TPK1-related disease, with a high level
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of sensitivity; reported patients harbouring TPK1 mutations in whom whole blood or plasma TPP was
measured (7/13) exhibited reduced concentrations (Table 1). There are a number of analytical methods
for Vitamin B1 measurement described in the literature, with high performance liquid chromatography
(HPLC) and fluorescence detection of oxidised thiamine derivatives being the most commonly
used [13,14]. The availability of numerous laboratory techniques to measure TPP levels, in addition
to variations in sample size, demographics, and dietary intake of control samples, has potentially
contributed towards observed differences in reported TPP reference ranges, with the bottom end being
between 63 and 105 nmol/L [15]. Regardless of the methodology, the most common derivative measured
in blood is TPP given that this is the most abundant form of Vitamin B1 present. However, additional
phosphorylated and unphosphorylated forms of thiamine are observed using HPLC chromatograms
and can be identified with reference to standards, albeit at low abundance, and sometimes at the limit
of quantitation [13,16]. Recently described methods [16–18], using HPLC with fluorescence or mass
spectrometric detection, can quantify other forms of thiamine. These methods have potential utility
during the investigation of inborn errors of thiamine metabolism using biological samples where other
thiamine species are more abundant. For example, in cerebrospinal fluid, thiamine and TMP are more
abundant than TPP. In our patient, a commercially available vitamin B1 HPLC kit (Chromsystems
Instruments and Chemicals GmbH, Munich, Germany) and an in-house derived reference range
(67–265 nmol/L) was used to quantify TPP. The Chromsystems method extracts and derivatises vitamin
B1 species from whole blood and then separates and detects these species by isocratic HPLC with
fluorescence detection (https://www.chromsystems.com). Although this method is not designed to
measure other forms of Vitamin B1, these can be observed as extra peaks in the chromatograms. This is
particularly useful once the patient has commenced thiamine supplementation as prominent thiamine
and TMP peaks are observed (Figure 4).
Table 1. Molecular and functional characteristics of reported TPK1 mutations.
ID TPK1 Mutations Predicted Effect on Protein TPP Levels Western Blot Reference
P1 c.[148A>C];[501+4A>T] p.[Asn50His];[Val119_Pro167del] N/A N/A Mayr et al. [6]
P2 c.[148A>C];[501+4A>T] p.[Asn50His];[Val119_Pro167del] 68 * (B) ↓hTPK1 Mayr et al. [6]
P3 c.[119T>C];[119T>C] p.[Leu40Pro)];[Leu40Pro] 50.4 * (B) ↓hTPK1 Mayr et al. [6]
P4 c.[119T>C];[119T>C] p.[Leu40Pro)];[(Leu40Pro] N/A N/A Mayr et al. [6]
P5 c.[179_182delGAGA];[656A>G] p.[Arg60LysfsTer52];[Asn219Ser] 96.9 * (B) ↓hTPK1 Mayr et al. [6]
P1
(P76 in [5]) c.[604T>G];[604T>G] p.[Trp202Gly];[Trp202Gly] N/A N/A Fraser et al. [8]
P2
(P77 in [5]) c.[604T>G];[604T>G] p.[Trp202Gly];[Trp202Gly] N/A N/A Fraser et al. [8]
P1
(P79 in [5]) c.[479C>T];[479C>T] p.[Ser160Leu];[Ser160Leu] 60.9 ˆ (B) Normal Banka et al. [7]
P2 c.[664G>C];[664G>C] p.[Asp222His];[Asp222His] 85.4 ˆ (B) ↓hTPK1 Banka et al. [7]
N/A c.[656A>G];deletion of exons 3and 4 on mRNA studies p.[Asn219Ser];[?] N/A N/A Invernizzi et al. [9]
Proband c.[119T>C];[119T>C] p.[Leu40Pro];[Leu40Pro] 32 ~ (P) N/A Mahajan et al. [10]
Sister c.[119T>C];[119T>C] p.[Leu40Pro];[Leu40Pro] N/A N/A Mahajan et al. [10]
P78 c.[365T>C];[365T>C] p.[Ile122Thr];[Ile122Thr] N/A N/A Ortigoza-Escobar et al.[5]
Proband c.[258+1G>A];[426G>C] p.[Leu142Phe];[?] 35 † (B) ↓hTPK1 Present study
Brother c.[258+1G>A];[426G>C] p.[Leu142Phe];[?] N/A N/A Present study
Abbreviations: B, Blood; N/A, Not Available; P, Plasma; TPP, thiamine pyrophosphate. * Mayr et al. TPP reference
range 132–271 nmol/L; ˆ Banka et al. TPP reference range 132.2–271 nmol/L; ~ Mahajan et al. TPP reference range
38–122 ng/L; † Present study TPP reference range 67–265 nmol/L.
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Figure 4. High performance liquid chromatography (HPLC) after 24 months of supplementation with
thiamine. Red line: patient. Blue line: control. In patient there is a prominent peak for thiamine
monophosphate (TMP) and unphosphorylated thiamine (thiamine) compared to control. These are
caused by a reduced conversion of thiamine and TMP to thiamine diphosphate/pyrophosphate (TPP)
for a deficient hTPK1 activity.
4. Conclusions
In conclusion, TPK1-related diseases pose a significant diagnostic challenge, given their
clinical heterogeneity and overlap with other inherited metabolic and mitochondrial disorders.
However, recognition is crucial to enable early therapeutic intervention with thiamine. TPP blood
measurement represents a fast and cost-effective screening tool for suspected TPK1-related disorders
to direct genetic testing and help filter potentially pathogenic variants generated by high-throughput
sequencing methods. Research is ongoing to investigate our cohorts of children and adults with
confirmed inborn errors of metabolism to evaluate the sensitivity and specificity of TPP measurement
in this population.
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Appendix A
The study was performed under the ethical guidelines issued by our institution, with written
informed consent obtained from participants for genetic studies.
Whole Exome Sequencing
Genomic DNA was extracted from peripheral leukocytes and prepared using Agilent SureSelect
Target Enrichment Kit preparation guide and sequenced on HiSeq 2000/2500 sequencer (Illumina).
The Illumina fastq sequencing data was mapped to the human reference assembly, hg19 (GRCh37;
UCSC genome browser), and variants were called using GATK. Filtering of variants was performed
using VarAft platform [19]. Variants with a MAF of≥0.01 in gnomAD, and 1000 Genomes databases and
synonymous and deep intronic variants were excluded from further evaluation. Variants within genes
encoding mitochondrial-localized proteins (n = 1158, Mitocarta) were first considered. If no candidate
mitochondrial disease-related genes were identified, variants in all coding genes were analyzed.
Western Blot Analysis
For western blot analysis, 10,000× g supernatants of fibroblast homogenates were used.
Proteins were separated on a 10% acrylamide/bisacrylamide gel and transferred to nitrocellulose
membranes (Biorad, Trans-Blot® Turbo™ Mini Nitrocellulose Transfer Packs, #1704158) using the
Transblot Turbo System (Biorad). The membranes were washed in Tris-buffered saline (TBS) for 5 min,
air-dried for 30 min, then blocked for 30 min at room temperature in Western Blocking Reagent (Roche,
#11921673001), and dissolved in TBS-T (0.5% Tween-20). After washing with TBS-T, the membranes
were incubated with the primary antibody diluted in 1x Western Blocking Reagent Solution in TBS-T. The
western blot was incubated with the following antibodies: polyclonal rabbit anti-TPK1 (Sigma-Aldrich,
HPA021849, overnight at 4 ◦C, 1:1000) and polyclonal rabbit anti-glucose-6-phosphate isomerase
(Santa Cruz, sc-33777, 1 h, room temperature, 1:1000). After washing with TBS-T, the membranes
were incubated with the secondary antibody (Dako, Dako EnVision+ System-HRP Labelled Polymer
Anti-Rabbit, K4003, 1 h, room temperature, 1:100 in 1×Western Blocking Reagent Solution in TBS-T).
For horse-radish peroxidase (HRP), detection the Lumi-LightPLUS Western Blotting Substrate (Roche,
#12015196001) was used.
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